In the Phase 2 study evaluating berzosertib with gemcitabine and cisplatin, cytopenias led to patients receiving lower cumulative doses of cisplatin, likely compromising efficacy in bladder cancer.30 Therefore, future studies will need to consider these DLTs when combining agents with ATR inhibitors. The gene discussed is ATR; the disease is urinary bladder cancer.